Skip to main content
SpringerLink
Log in
Book cover

Immunotherapy of Cancer pp 143–158Cite as

Personalized Peptide Vaccine

  • Chapter
  • First Online:

  • 2213 Accesses

Abstract

Selection of suitable peptide vaccines for individual patients based on the preexisting host immunity before vaccination could induce potent antitumor responses that provide clinical benefit to cancer patients. We have developed a novel immunotherapeutic approach of personalized peptide vaccination (PPV) in which a maximum of four human leukocyte antigen (HLA) class IA-matched peptides are selected for vaccination among pooled peptides on the basis of both HLA class IA type and the preexisting host immunity before vaccination. We conducted a series of phase I and phase II clinical trials of PPV, which have shown better antigen-specific immune responses and promising clinical outcomes in patients with various types of advanced cancers. Further randomized phase III trials would be recommended to prove the clinical benefits of PPV. In addition, novel biomarkers for selecting patients who would benefit most from PPV remain to be identified.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104:599–613

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    Article  PubMed  CAS  Google Scholar 

  3. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K (2010) Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer 46:1514–1519

    Article  PubMed  Google Scholar 

  5. Noguchi M, Yao A, Harada M, Nakashima O, Komohara Y, Yamada S et al (2007) Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 67:933–942

    Article  PubMed  CAS  Google Scholar 

  6. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647

    Article  PubMed  Google Scholar 

  7. Türeci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ et al (1996) The SSX-2 gene, which is involved in the t(X; 18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 56:4766–4772

    PubMed  Google Scholar 

  8. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56:2479–2483

    PubMed  CAS  Google Scholar 

  9. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404–414

    Article  PubMed  CAS  Google Scholar 

  11. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–2127

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. Yamada A, Sasada T, Noguchi M, Itoh K (2013) Next-generation peptide vaccines for advanced cancer. Cancer Sci 104:15–21

    Article  PubMed  CAS  Google Scholar 

  13. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M et al (2010) A new era in anticancer peptide vaccines. Cancer 116:2071–2080

    PubMed  CAS  Google Scholar 

  14. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570

    Article  PubMed  CAS  Google Scholar 

  15. Bei R, Scardino A (2010) TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. J Biomed Biotechnol 2010:102758. doi:10.1155/2010/102758

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17:51–88

    Article  PubMed  CAS  Google Scholar 

  17. Chen W, McCluskey J (2006) Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res 95:203–247

    Article  PubMed  CAS  Google Scholar 

  18. Itoh K, Yamada A (2006) Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 97:970–976

    Article  PubMed  CAS  Google Scholar 

  19. Mochizuki K, Sato Y, Tsuda N, Shomura H, Sakamoto M, Matsuura K et al (2004) Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 25:121–131

    PubMed  CAS  Google Scholar 

  20. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G (2009) Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 9:1043–1055

    Article  PubMed  CAS  Google Scholar 

  21. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A et al (2000) Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 164:2565–2574

    Article  PubMed  CAS  Google Scholar 

  22. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F et al (1998) A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187:277–288

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  23. Harashima N, Tanaka K, Sasatomi T, Shimizu K, Miyagi Y, Yamada A et al (2001) Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 31:323–332

    Article  PubMed  CAS  Google Scholar 

  24. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K (2001) Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 61:6459–6466

    PubMed  CAS  Google Scholar 

  25. Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K (2003) Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate 57:152–159

    Article  PubMed  CAS  Google Scholar 

  26. Inoue Y, Takaue Y, Takei M, Kato K, Kanai S, Harada Y et al (2001) Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J Urol 166:1508–1513

    Article  PubMed  CAS  Google Scholar 

  27. Kobayashi K, Noguchi M, Itoh K, Harada M (2003) Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci 94:622–627

    Article  PubMed  CAS  Google Scholar 

  28. Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T et al (2011) Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases. Oncol Rep 25:57–62

    PubMed  Google Scholar 

  29. Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K et al (2011) Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 10:1266–1279

    Article  CAS  Google Scholar 

  30. Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E et al (2010) Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 5:e12670

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y et al (2012) CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother 61:561–571

    Article  PubMed  CAS  Google Scholar 

  32. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351–360

    Article  PubMed  CAS  Google Scholar 

  33. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH (2007) CD8+ CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179:5033–5040

    Article  PubMed  CAS  Google Scholar 

  34. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 93:7855–7860

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  35. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP et al (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14:169–177

    Article  PubMed  CAS  Google Scholar 

  36. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838–1847

    Article  PubMed  CAS  Google Scholar 

  37. Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE et al (2009) Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 125:2104–2113

    Article  PubMed  CAS  Google Scholar 

  38. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM et al (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14:178–187

    Article  PubMed  CAS  Google Scholar 

  39. Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K (2011) A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71:470–479

    Article  PubMed  CAS  Google Scholar 

  40. Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A et al (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57:80–92

    Article  PubMed  CAS  Google Scholar 

  41. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K et al (2004) Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 95:77–84

    Article  PubMed  CAS  Google Scholar 

  42. Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J et al (2007) Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res 16:341–349

    PubMed  Google Scholar 

  43. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y et al (2009) A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 59:1001–1009

    Article  CAS  Google Scholar 

  44. Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S et al (2012) Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate 72:834–845

    Article  PubMed  CAS  Google Scholar 

  45. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M et al (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11:5900–5911

    Article  PubMed  CAS  Google Scholar 

  46. Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K et al (2011) Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen–A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29:337–344

    Article  PubMed  CAS  Google Scholar 

  47. Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, Takahashi K et al (2007) Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98:605–611

    Article  PubMed  CAS  Google Scholar 

  48. Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T et al (2010) A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 24:795–801

    PubMed  CAS  Google Scholar 

  49. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  50. Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S et al (2012) Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 3:463–469

    PubMed Central  PubMed  CAS  Google Scholar 

  51. Ito M, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, Yamada A et al (2000) Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 88:633–639

    Article  PubMed  CAS  Google Scholar 

  52. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H et al (1999) Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59:4056–4063

    PubMed  CAS  Google Scholar 

  53. Sato Y, Maeda Y, Sasatomi T, Takahashi M, Une Y, Kondo M et al (2004) A phase I trial of CTL-precursor-oriented peptide vaccine for colorectal carcinoma patients. Br J Cancer 90:13334–13342

    Article  CAS  Google Scholar 

  54. Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y et al (2007) Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 98:1113–1119

    Article  PubMed  CAS  Google Scholar 

  55. Sato Y, Shomura H, Maeda Y, Mine T, Une Y, Akasaka Y et al (2003) Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94:802–808

    Article  PubMed  CAS  Google Scholar 

  56. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T et al (2003) Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 94:548–556

    Article  PubMed  CAS  Google Scholar 

  57. Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A et al (2012) Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 40:1492–1500

    PubMed  CAS  Google Scholar 

  58. Terazaki Y, Yoshiyama K, Matsueda S, Watanabe N, Kawahara A, Naito Y et al (2012) Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci 103:638–644

    Article  PubMed  CAS  Google Scholar 

  59. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A et al (2004) Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 27:60–67

    Article  PubMed  CAS  Google Scholar 

  60. Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M et al (2007) Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci 98:1965–1968

    Article  PubMed  CAS  Google Scholar 

  61. Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K et al (2003) Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother 26:357–366

    Article  PubMed  CAS  Google Scholar 

  62. Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M et al (2011) A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int 108:831–838

    Article  PubMed  CAS  Google Scholar 

  63. Eggermont AM (2009) Therapeutic vaccines in solid tumours: can they be harmful? Eur J Cancer 45:2087–2090

    Article  PubMed  CAS  Google Scholar 

  64. Disis ML (2011) Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60:433–442

    Article  PubMed  CAS  Google Scholar 

  65. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388–1397

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  66. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK et al (2011) Autoimmunity associated with immunotherapy of cancer. Blood 118:499–509

    Article  PubMed  CAS  Google Scholar 

  67. López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE et al (2009) Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 27:945–952

    Article  PubMed  CAS  Google Scholar 

  68. Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M et al (2012) Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 118:3208–3221

    Article  PubMed  CAS  Google Scholar 

  69. Sansone P, Bromberg J (2012) Targeting the interleukin-6/jak/stat pathway in human malignancies. J Clin Oncol 30:1005–1014

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  70. Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2:619–626

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure Statement

The author indicated no potential conflict of interest.

Author information

Authors and Affiliations

  1. Clinical Research Division of Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan

    Masanori Noguchi M.D., Ph.D.

Authors
  1. Masanori Noguchi M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masanori Noguchi M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Clinical Oncology, Kawasaki Medical School, Okayama, Japan

    Yoshiyuki Yamaguchi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Noguchi, M. (2016). Personalized Peptide Vaccine. In: Yamaguchi, Y. (eds) Immunotherapy of Cancer. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55031-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55031-0_11

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55030-3

  • Online ISBN: 978-4-431-55031-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation